Compare Adaptive Biotechnologies Corp (ADPT) vs Beyond Meat Inc (BYND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Beyond Meat Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Beyond Meat Inc trades at $0.68 (market cap $366.00M). The key difference: Adaptive Biotechnologies Corp is far larger — about 9.1× Beyond Meat Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | BYND | |
|---|---|---|
Market Cap | $3.33B | $366.00M |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $4.28 |
52-Week Low | $10.24 | $0.52 |
Enterprise Value | $3.19B | $675.99M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BYND trades at $0.7102, down slightly by 0.01% on the day, with a neutral technical signal and bearish moving averages. The company reported a net income of $178.01M in 2025, a significant turnaround from prior losses, though revenue declined to $275.50M. Recent news highlights expansion of Beyond Steak Filet into major retailers like Meijer and Wegmans, alongside new product launches such as Beyond Immerse protein drinks, aiming to revive growth amid challenging sales trends.
The outlook remains cautious due to persistent revenue declines and negative cash flow from operations, offset by strong profitability margins and positive net income. Risks include execution challenges in new product categories and high sell-side analyst skepticism, with 57.14% recommending sell. Investment opportunity hinges on successful turnaround efforts driving sustainable top-line growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →
